For patients living with Long COVID, ME/CFS, chronic Lyme, fibromyalgia, and other chronic inflammatory conditions — a targeted clinical protocol from Celly Health Medical Group, with medications priced through Celly Rx.
A growing body of clinical research identifies chronic systemic inflammation as a root-cause driver — not just a downstream symptom — of conditions including:
These conditions share a common substrate: dysregulated immune activation that persists in the vascular endothelium long after the initial trigger has resolved — producing fatigue, brain fog, post-exertional malaise, dysautonomia, and chronic pain.
Non-classical monocytes expressing the CCR5 and CX3CR1 (fractalkine) receptors persist in the vascular endothelium, driving a chronic inflammatory state. This monocytic-endothelial-platelet axis is targetable — but conventional anti-inflammatory drugs (NSAIDs, corticosteroids) can’t reach it.
The Chronic Inflammation Protocol targets this axis directly. By blocking CCR5 receptor activity at the immune-cell level, the protocol prevents monocyte adhesion, reduces endothelial activation, and suppresses the cytokine cascade that drives chronic vascular inflammation.
The result, in patients who respond, is a measurable reduction in inflammatory biomarkers and improvement in fatigue, cognitive function, and post-exertional malaise.
FDA-approved CCR5 receptor antagonist (originally indicated for HIV-1)
Maraviroc binds selectively to the CCR5 receptor on the cell membrane, blocking the interaction between CCR5-expressing non-classical monocytes and the vascular endothelium. This disrupts the inflammatory cascade at the immune-cell level — preventing monocyte adhesion, reducing endothelial activation, and suppressing the release of pro-inflammatory cytokines (TNF-α, IL-6, IL-2, VEGF) that drive chronic vascular inflammation.
Check maraviroc pricing →FDA-approved HMG-CoA reductase inhibitor with pleiotropic anti-inflammatory effects
Atorvastatin is included for its pleiotropic — non-cholesterol — effects on endothelial function. Independent of its lipid-lowering action, atorvastatin improves nitric-oxide bioavailability, reduces vascular oxidative stress, and complements maraviroc’s upstream blockade of inflammatory cell trafficking.
Check atorvastatin pricing →The protocol is indicated for evaluation in patients with chronic inflammatory conditions characterized by persistent symptoms lasting 12+ weeks following an acute inflammatory trigger — viral infection, tick-borne illness, autoimmune flare, or idiopathic origin.
With post-exertional malaise — the hallmark of ME/CFS and Long COVID. Symptoms worsen disproportionately after physical or cognitive activity.
POTS, orthostatic intolerance, exaggerated heart-rate response, dysautonomia — signs of nervous system dysregulation tied to chronic inflammation.
Brain fog, word-finding difficulty, slowed processing speed, memory complaints — in the absence of an alternative neurologic diagnosis.
Diffuse myalgia, neuropathic pain, fibromyalgia-pattern presentations where imaging and standard workup don’t explain the symptom burden.
Documented elevation of CRP, abnormal cytokine panels (IncellKINE 14-marker), elevated D-dimer or ferritin, or Long Hauler Index findings.
Patients whose symptoms have not improved with NSAIDs, corticosteroids, antidepressants, or symptomatic therapy — and who are seeking a mechanism-based approach.
Comprehensive intake covering symptom history, prior workup, and trigger event. Standardized inventories: fatigue severity scale, COMPASS-31 autonomic assessment, cognitive function questionnaire, pain scale, functional capacity rating.
IncellKINE 14-marker cytokine panel, baseline labs (CBC, CMP, CRP, D-dimer, ferritin), and any indicated additional testing (thyroid, vitamin D, autoimmune panel) to rule out alternative diagnoses.
Cytokine panel results are reviewed against validated thresholds. Patients with elevated CCR5-related inflammatory markers and qualifying symptomatic presentation are considered for protocol initiation. Provider retains full clinical autonomy.
Initial treatment course with follow-up cytokine panels at weeks 4, 8, and 12 to assess response. Dose adjustments and continuation decisions are made based on biomarker trajectory and symptom response.
Integration into the Celly Health Direct Primary Care model: ongoing primary care, lifestyle medicine support, medication adherence monitoring through Celly Rx, and periodic reassessment.
This is a clinical evaluation pathway operated by licensed providers within Celly Health Medical Group. It is not a self-administered program. It is not a guarantee of treatment — not every patient meets criteria for protocol initiation, and provider judgment governs prescribing in every case.
Maraviroc is FDA-approved for HIV-1 infection. Use of maraviroc for chronic inflammatory conditions is off-label. Off-label prescribing is legal and common in U.S. medicine when supported by clinical evidence and provider judgment, but patients should understand this distinction before pursuing the protocol.
The CCR5-antagonist approach to chronic post-viral inflammation has been studied through the IncellDx / HealthBio clinical program, with pre-trial data spanning thousands of treated patients. A randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial (252 patients, 32 weeks) has been accepted by the FDA through the 505(B)(2) pathway, with patient pre-enrollment underway.
The underlying intellectual property is protected by USPTO Patent #11,180,491b2. Future research targets include ME/CFS, chronic Lyme, fibromyalgia, and Alzheimer’s-related neuroinflammation.
The first step is a clinical conversation. Reach out to Celly Health Medical Group to learn whether the Chronic Inflammation Protocol is right for you.
Disclosure. The Chronic Inflammation Protocol described here is a clinical program of Celly Health Medical Group operated independently of Celly Rx. Celly Rx is a prescription discount program and does not provide medical care, make treatment decisions, or guarantee any clinical outcome. Use of any specific medication is determined by a licensed prescribing provider based on individual clinical evaluation. Maraviroc is FDA-approved for HIV-1; use for chronic inflammatory conditions is off-label.
The Meraverock protocol designation, formulary structure, and clinical decision pathway constitute proprietary clinical infrastructure of Celly Health and its affiliated entities. Trial and IP references reflect publicly available information regarding the IncellDx / HealthBio clinical development program at the time of writing.